Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers-Reference-Cited by-同舟云学术

Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers

Published:2024-01-08 Issue:1 Volume:20 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Tamrakar Dipesh¹^ORCID,Poudel Pranodan¹,Thapa Pragya¹,Singh Srijana¹,Khadgi Amit¹,Thapa Sameera¹,Tamrakar Rajendra¹,Shrestha Anmol¹,Madhup Surendra¹,Rai Ganesh Kumar²,Gupta Birendra Prasad³,Saluja Tarun³,Sahastrabuddhe Sushant³,Shrestha Rajeev¹

Affiliation:

1. Dhulikhel Hospital, Kathmandu University Hospital, Dhulikhel, Nepal

2. Kanti Children Hospital, Kathmandu, Nepal

3. International Vaccine Institute, Seoul, Republic of Korea

Funder

Bill & Melinda Gates Foundation

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2301631

Reference33 articles.

1. Progress in Typhoid Fever Epidemiology

2. The Invisible Burden: Diagnosing and Combatting Typhoid Fever in Asia and Africa

3. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017

4. Geographical distribution of typhoid risk factors in low and middle income countries

5. The Burden of Typhoid and Paratyphoid in India: Systematic Review and Meta-analysis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse events associated with teriparatide: a real-world disproportionality analysis of the FDA adverse event reporting system (FAERS);Expert Opinion on Drug Safety;2024-08-19